To include your compound in the COVID-19 Resource Center, submit it here.

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal.

The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain its profitability and signaled an interest in new business development opportunities in its core focus areas of CNS and oncology (see "Alkermes Restructures”).

On Monday, Alkermes said

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers